[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622994":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":65,"collaborators":26,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine injection","ACTIVE_COMPARATOR","2%preservative-free without vasocostrictor injectable solution, 1.8 ml per injection point.",[13],"Drug: Lidocaine 2% (preservative-free, without vasoconstrictor)",{"label":15,"type":16,"description":17,"interventionNames":18},"Injection of Magnesium sulfate with Lidocaine","EXPERIMENTAL","10% injectable solution (100 mg\u002Fml), from certified supplier. Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄)",[19],"Drug: Lidocaine 2% + Magnesium Sulfate 10% (combination)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Lidocaine 2% (preservative-free, without vasoconstrictor)","Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor, 1.8 ml at the most painful trigger points with \"Fast-in, fast out\" or \"peppering\" method and inject the solution slowly.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Lidocaine 2% + Magnesium Sulfate 10% (combination)","Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor mixed with 10%magnesium sulphate , Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄) at the most painful trigger points with \"Fast-in, fast out\" or \"peppering\" method and inject the solution slowly.",[15],[32],{"name":33,"affiliation":34,"role":35},"Maii E Abdelazeem, Bsc","Faculty of Oral & Dental Medicine, Cairo University","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Maii E Abdelazeem, BSc","CONTACT","+20 1013988933","Maii.emad@dentistry.cu.edu.eg",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":26},"Khaled A Elhayes, PhD","+20 1030000360",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Faculty of oral and dental medicine, cairo university","RECRUITING","Giza","Giza Governorate","12613","Egypt","EG",{"type":55,"coordinates":56},"Point",[57,58],31.20861,30.00944,{"lat":58,"lon":57},[61,63],{"name":38,"role":39,"phone":62,"phoneExt":26,"email":41},"01013988933",{"name":64,"role":39,"phone":26,"phoneExt":26,"email":26},"Khaled A Elhayes, Phd",{"type":35,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Maii Emad Abdelazeem","Principle investigator","100622994","magnesium-sulfate-as-an-adjuvant-to-lidocaine-in-mpds-trigger-point-injections-assessed-by-vas-and-semg-100622994",false,"NCT07390851","Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.","Evaluation of the Effect of Adding Magnesium Sulfate to Lidocaine in the Treatment of Myofascial Pain Dysfunction Syndrome Using Surface Electromyography (sEMG).(Randomized Clinical Trial)","Inclusion Criteria:\n\n1. Age between 18 and 70 years.\n2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).\n3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).\n4. Pain duration ≥ 3 months.\n5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS).\n6. Noprior trigger point injection in the affected area within the past 3 months.\n7. Ability and willingness to provide informed consent.\n8. Compliance with study visits and procedures\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.\n2. Current use of anticoagulants or history of bleeding disorders.\n3. Systemic or local infection at or near the injection site.\n4. History of fibromyalgia, central pain syndromes, or cancer-related pain.\n5. Major psychiatric illnesses (e.g., schizophrenia, severe depression).\n6. Recent surgery or trauma to the head, neck, or upper back (\\\u003C6 months).\n7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention.\n8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.","ALL","18 Years","70 Years",{"count":79,"type":80},28,"ESTIMATED","INTERVENTIONAL",[83],"NA","Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.",[86],"Myofascial Pain Dysfunction Syndrome",[88,89,90,91,92],"Trigger points injection","Myofascial Pain Dysfunction Syndrome (MPDS)","Magnesium Sulfate","Surface Electromyography","Visual Analog Scale","2026-02-01",{"date":95,"type":96},"2026-02-05","ACTUAL",{"date":98,"type":96},"2025-11-26",{"date":100,"type":80},"2026-11-26",{"name":5,"class":6},1]